3M is a diversified industrial and consumer products conglomerate that has been working through one of the more turbulent chapters in its history. After shedding its healthcare segment and settling major litigation, the company has stabilized its profitability, posting solid operating and net margins in 2024 and into 2025 — but revenue has shrunk meaningfully from its peak, reflecting both divestitures and organic headwinds. The balance sheet carries elevated debt relative to equity, and that leverage has risen further as of the most recent quarter. Capital spending has been cut back sharply. In short, 3M looks more financially disciplined than it did a few years ago, but it is a smaller, more leveraged company than it was at its peak, and revenue growth remains elusive.
Snapshot & Big Picture
3M (NYSE: MMM) is one of America's most iconic industrial conglomerates, known for products ranging from Post-it Notes and Scotch tape to industrial abrasives, filtration systems, and safety equipment. The company operates globally across multiple business segments. The last decade has been marked by significant legal liabilities — primarily related to PFAS chemicals and combat arms earplugs — whose settlement costs drove a dramatic, one-time loss in fiscal year 2023. With those settlements largely resolved and the healthcare business (Solventum) spun off in 2024, 3M is now a leaner entity. The top-line figures in 2021 and prior years include healthcare revenue that is no longer part of the company, which is important context when reading the multi-year trend.
| Fiscal Year | Revenue | EBITDA | Operating Margin | Net Margin |
|---|---|---|---|---|
| 2016 | $30.1B | $8.5B | 23.3% | 16.8% |
| 2017 | $31.7B | $9.2B | 24.3% | 15.3% |
| 2018 | $32.8B | $8.7B | 22.0% | 16.3% |
| 2019 | $32.1B | $7.8B | 19.2% | 14.1% |
| 2020 | $32.2B | $9.1B | 22.3% | 16.9% |
| 2021 | $35.4B | $9.3B | 20.8% | 16.7% |
| 2022 | $26.2B | $6.2B | 16.7% | 22.1% |
| 2023 | $24.6B | -$8.7B | -43.4% | -28.4% |
| 2024 | $24.6B | $6.2B | 19.6% | 17.0% |
| 2025 | $24.9B | $5.9B | 18.6% | 13.0% |
Latest Quarter Snapshot
The most recent data available comes from 3M's 10-Q filing for the quarter ended June 30, 2026, which is more current than the annual figures above. Revenue for the quarter came in at $6.5 billion, with an operating margin of 15.1% and a net margin of 14.4%. EBITDA for the quarter was $1.31 billion. The current ratio stood at 1.24, which is adequate but tighter than the full-year 2025 figure of 1.71, suggesting some working capital pressure in the most recent period. Most notably, the debt-to-equity ratio jumped to 4.25 as of June 2026, up from 2.68 at fiscal year-end 2025 and 3.40 at year-end 2024 — a meaningful increase in financial leverage that warrants monitoring. Capital expenditures for the quarter were $225 million, representing a capex-to-revenue ratio of 3.5%, consistent with the lower reinvestment pace seen in recent annual periods. Gross margin was not reported in the filing for this period.
Profitability
3M's profitability story over the past decade is one of gradual compression punctuated by a catastrophic 2023. Operating margins peaked around 24% in 2017 and trended downward through 2019 and into the litigation years, before collapsing to -43% in 2023 — entirely driven by litigation settlement charges, not operational deterioration. The business recovered sharply in 2024, with operating margin rebounding to 19.6% and net margin reaching 17.0%, among the best in the dataset. In 2025, margins moderated slightly to 18.6% operating and 13.0% net. The Q2 2026 operating margin of 15.1% is a step down from recent annual figures, though single quarters can be lumpy. Overall, the core operating business appears to have returned to reasonable health after the 2023 disruption, though it has not yet recaptured the margin highs of 2016–2017.
Financial Health
3M's balance sheet has become considerably more leveraged over time. Debt-to-equity was around 1.0x in 2016 and 2017, climbed through the litigation years, and now stands at 4.25x as of June 2026 — the highest level in this dataset. This reflects both the costs of litigation settlements and the effects of the Solventum spin-off on the equity base. The current ratio has remained above 1.0x throughout, indicating the company can cover near-term obligations, though it has trended down from the highs of 1.88x in 2018–2020 to 1.24x in the most recent quarter.
On capital expenditures, 3M has been visibly pulling back on reinvestment. Capex peaked at $1.75 billion in 2022 (6.7% of revenue) and has fallen steadily: $1.62 billion in 2023, $1.18 billion in 2024, and $910 million in 2025 — with the most recent quarter annualizing to roughly $900 million. The capex-to-revenue ratio has similarly dropped from the 6–7% range in 2022–2023 to roughly 3.7% in 2025 and 3.5% in the latest quarter. This declining capital intensity suggests 3M is prioritizing cash preservation and debt reduction over aggressive expansion, which is consistent with a company digesting large legal settlements and managing elevated leverage. The flip side is that sustained underinvestment could weigh on long-term competitiveness.
Growth
| Window | Start Fiscal Year | End Fiscal Year | Start Revenue | End Revenue | CAGR |
|---|---|---|---|---|---|
| 3-Year | 2022 | 2025 | $26.2B | $24.9B | -1.6% |
| 5-Year | 2020 | 2025 | $32.2B | $24.9B | -5.0% |
| 10-Year | N/A | N/A | N/A | N/A | Not available |
Note on the 10-year CAGR: This window is not available in the dataset provided. Based on the data at hand, the earliest annual filing included is fiscal year 2016, which does not provide a full 10-year span ending in 2025 from a computed baseline — the pre-calculated figure was returned as null.
The CAGR figures tell a clear story: 3M's revenue has been shrinking in both the 3-year and 5-year windows, declining at -1.6% and -5.0% annually, respectively. Much of the 5-year decline reflects the Solventum healthcare spin-off, which removed a large revenue stream from the consolidated results, as well as the step-down in reported revenue after 2021. Even adjusting for the spin-off, organic growth has been modest at best. Until 3M demonstrates consistent top-line expansion from its remaining business segments, revenue contraction will remain a central concern for fundamental investors.
Leave a Comment